Share Name Share Symbol Market Type
Merck Kgaa (PC) USOTC:MKKGY OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +$0.00 +0.00% $21.8025 $0.01 $22.03 - - - 0 01:00:00

Merck KGaA Gets FDA Breakthrough-Therapy Designation for Tepotinib

11/09/2019 11:49am

Dow Jones News


Merck Kgaa (USOTC:MKKGY)
Historical Stock Chart

1 Month : From Aug 2019 to Sep 2019

Click Here for more Merck Kgaa Charts.

By Colin Kellaher

 

Merck KGaA (MRK.XE) Wednesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to its tepotinib investigational therapy in a form of lung cancer.

The Darmstadt, Germany, science and technology company said the designation covers tepotinib in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.

The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.

Lung cancer is one of the most common types of cancer worldwide. Merck said alterations of the MET signaling pathway are found in 3% to 5% of non-small cell lung cancer cases and correlate with aggressive tumor behavior and poor clinical prognosis.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

September 11, 2019 06:34 ET (10:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Merck Kgaa Chart

1 Year Merck Kgaa Chart

1 Month Merck Kgaa Chart

1 Month Merck Kgaa Chart
Your Recent History
USOTC
MKKGY
Merck Kgaa
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190916 10:56:47